Non-small-cell lung cancer (NSCLC) predominantly occurs in the elderly, a group that has
been historically undertreated for various reasons such as perceived frailty and comorbidity …

Purpose To evaluate the efficacy and toxicities of erlotinib as first-line treatment for Asian
elderly patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods …

7080 Background: Chemotherapy for patients≥ 70 years of age with advanced NSCLC can
be associated with greater toxicities than in younger patients. The identification of an …

7168 Background: Elderly patients derive survival benefit but significant toxicity from
chemotherapy for NSCLC. Erlotinib is associated with reasonable toxicity and has a survival …

Background In this prospective non-interventional study, the effectiveness and tolerability of
erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after≥ 1 platinum …

7148 Background: Chemotherapy for patients≥ 70 with advanced NSCLC is associated
with survival benefits but with increased toxicity compared with younger patients. Erlotinib …

Background Targeting the epidermal-growth-factor-receptor (EGFR) in non-small cell lung
cancer (NSCLC) is an established treatment option with less toxicity compared to …

Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is
involved in cell proliferation, growth, migration, invasion and survival, and has been found to …

Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor, which is an effective treatment for patients with non-small cell lung cancer …

Aim Gefitinib and erlotinib are efficacious and safe for older patients with epidermal growth
factor receptor‐mutant non‐small cell lung cancer. However, prolonged use of epidermal …